Abstract

Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC EGFR-mutant patients who were treated with EGFR TKIs. Methods: Among the 580 consecutive NSCLC patients who were treated at our facility between 2008 and 2012, a total of 124 treatment-naïve, advanced NSCLC, EGFR-mutant patients treated with EGFR TKIs were identified and grouped into nonresponders and responders for analyses. Results: Of 124 patients, 104 (84%) responded to treatment, and 20 (16%) did not; and the overall median PFS was 9.0 months. Notably, the PFS, overall survival (OS) and survival rates were significantly unfavorable in non-responders (1.8 vs. 10.3 months, hazard ratio (HR) = 29.2, 95% confidence interval (CI), 13.48-63.26, P

Original languageEnglish
Article numbere83266
JournalPLoS One
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 23 2013

Fingerprint

lung neoplasms
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
tyrosine
phosphotransferases (kinases)
Cells
mutation
Mutation
Disease-Free Survival
cells
mutants
Survival
Therapeutics
epidermal growth factor receptors
confidence interval
Hazards
Survival Rate
survival rate
Confidence Intervals

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

@article{960cd87a965e4456b5e3297caa2711a2,
title = "Distinct clinical outcomes of non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: Non-responders versus responders",
abstract = "Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC EGFR-mutant patients who were treated with EGFR TKIs. Methods: Among the 580 consecutive NSCLC patients who were treated at our facility between 2008 and 2012, a total of 124 treatment-na{\"i}ve, advanced NSCLC, EGFR-mutant patients treated with EGFR TKIs were identified and grouped into nonresponders and responders for analyses. Results: Of 124 patients, 104 (84{\%}) responded to treatment, and 20 (16{\%}) did not; and the overall median PFS was 9.0 months. Notably, the PFS, overall survival (OS) and survival rates were significantly unfavorable in non-responders (1.8 vs. 10.3 months, hazard ratio (HR) = 29.2, 95{\%} confidence interval (CI), 13.48-63.26, P",
author = "Hsiao, {Shih Hsin} and Liu, {H. Eugene} and Lee, {Hsin Lun} and Lin, {Chii Lan} and Chen, {Wei Yu} and Wu, {Zhung Han} and Lin, {Sey En} and Chiang, {Ling Ling} and Chung, {Chi Li}",
year = "2013",
month = "12",
day = "23",
doi = "10.1371/journal.pone.0083266",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Distinct clinical outcomes of non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors

T2 - Non-responders versus responders

AU - Hsiao, Shih Hsin

AU - Liu, H. Eugene

AU - Lee, Hsin Lun

AU - Lin, Chii Lan

AU - Chen, Wei Yu

AU - Wu, Zhung Han

AU - Lin, Sey En

AU - Chiang, Ling Ling

AU - Chung, Chi Li

PY - 2013/12/23

Y1 - 2013/12/23

N2 - Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC EGFR-mutant patients who were treated with EGFR TKIs. Methods: Among the 580 consecutive NSCLC patients who were treated at our facility between 2008 and 2012, a total of 124 treatment-naïve, advanced NSCLC, EGFR-mutant patients treated with EGFR TKIs were identified and grouped into nonresponders and responders for analyses. Results: Of 124 patients, 104 (84%) responded to treatment, and 20 (16%) did not; and the overall median PFS was 9.0 months. Notably, the PFS, overall survival (OS) and survival rates were significantly unfavorable in non-responders (1.8 vs. 10.3 months, hazard ratio (HR) = 29.2, 95% confidence interval (CI), 13.48-63.26, P

AB - Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC EGFR-mutant patients who were treated with EGFR TKIs. Methods: Among the 580 consecutive NSCLC patients who were treated at our facility between 2008 and 2012, a total of 124 treatment-naïve, advanced NSCLC, EGFR-mutant patients treated with EGFR TKIs were identified and grouped into nonresponders and responders for analyses. Results: Of 124 patients, 104 (84%) responded to treatment, and 20 (16%) did not; and the overall median PFS was 9.0 months. Notably, the PFS, overall survival (OS) and survival rates were significantly unfavorable in non-responders (1.8 vs. 10.3 months, hazard ratio (HR) = 29.2, 95% confidence interval (CI), 13.48-63.26, P

UR - http://www.scopus.com/inward/record.url?scp=84893498040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893498040&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0083266

DO - 10.1371/journal.pone.0083266

M3 - Article

C2 - 24376677

AN - SCOPUS:84893498040

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e83266

ER -